is document about
has knowledgeable contact person
Documents and Publications  >  report  >  journal article  >  Immunotherapy of establishe...

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.

journal article

Melief CJ, van der Burg SH.
Nat Rev Cancer. 2008 May;8(5):351-60.

This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses. The most attractive vaccine compounds are synthetic long peptides (SLP) corresponding to the sequence of tumour viral antigens or tumour-associated non-viral antigens. Crucial to induction of therapeutic T-cell immunity is the capacity of SLP to deliver specific cargo to professional antigen-presenting cells (dendritic cells (DC)). Proper DC activation then induces the therapeutic CD4+ and CD8+ T-cell responses that are associated with regression of established (pre)malignant lesions, including those induced by high-risk human papilloma virus.


Pub Med:

created over 15 years ago (16 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF Rdf ]   [ RelFinder Relfinder ]